Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 37.24%916.96M | 118.00%485.19M | -8.09%175.71M | 14.43%174.51M | -19.96%81.55M | -7.29%668.14M | -20.46%222.56M | 10.86%191.18M | 152.51M | 101.89M |
Cost of revenue | 76.90%345.2M | 101.36%115.83M | 62.20%82.25M | 94.20%84.85M | 44.11%62.28M | 29.84%195.14M | -1.03%57.52M | 91.24%50.71M | 43.69M | 43.22M |
Gross profit | 20.88%571.76M | 123.80%369.36M | -33.47%93.46M | -17.60%89.67M | -67.15%19.27M | -17.08%473M | -25.55%165.04M | -3.74%140.47M | 108.82M | 58.67M |
Operating expense | 7.17%593.42M | -3.94%136.91M | 11.05%165.73M | 0.24%133.71M | 22.19%157.08M | 4.36%553.7M | -8.60%142.52M | 4.56%149.24M | 133.39M | 128.55M |
Operating profit | 73.15%-21.67M | 932.43%232.45M | -723.71%-72.27M | -79.26%-44.04M | -97.21%-137.8M | -302.45%-80.71M | -65.76%22.52M | -374.36%-8.77M | -24.57M | -69.88M |
Net non-operating interest income (expenses) | 39.83%-142K | 39.53%-52K | -8.33%-65K | 96.30%-236K | 92.82%-86K | -60K | ||||
Non-operating interest income | -11.11%8K | ---- | ---- | ---- | ---- | 200.00%9K | ---- | ---- | ---- | ---- |
Total other finance cost | -38.78%150K | -36.84%60K | 0.00%60K | ---- | ---- | -96.16%245K | -92.08%95K | --60K | ---- | ---- |
Net investment income | 160.53%664K | 425.00%294K | 2,912.00%703K | -12,088.89%-1.1M | 56K | -112,700.00%-1.13M | 0 | -25K | ||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 120.89%47K | 33.23%-225K | 171.62%53K | -529.41%-73K | 21K | -226K | ||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 0 | 0 | ||||||||
Less:Write off | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
Other non-operating income (expenses) | -95.79%82K | -103.08%-32K | -697K | 804K | 7K | 116.36%1.95M | 424.69%1.04M | 0 | ||
Income before tax | 73.84%-21.01M | 887.03%232.71M | -624.11%-72.66M | -85.26%-43.97M | -95.49%-137.09M | -477.31%-80.32M | -63.25%23.58M | 25.64%-10.04M | -23.73M | -70.13M |
Income tax | -99.65%158K | -75.82%571K | -98.62%573K | -525.83%-2.44M | 154.20%1.45M | 294.78%45.08M | 109.50%2.36M | 2,544.85%41.58M | 573K | 572K |
Net income | 83.12%-21.17M | 994.23%232.14M | -41.90%-73.24M | -70.86%-41.53M | -95.96%-138.55M | -382.22%-125.4M | -76.17%21.22M | -242.55%-51.61M | -24.3M | -70.7M |
Net income continuous operations | 83.12%-21.17M | 994.18%232.14M | -41.90%-73.24M | -70.86%-41.53M | -95.97%-138.55M | -382.22%-125.4M | -76.17%21.22M | -242.55%-51.61M | ---24.31M | ---70.7M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 83.12%-21.17M | 994.23%232.14M | -41.90%-73.24M | -70.86%-41.53M | -95.96%-138.55M | -382.22%-125.4M | -76.17%21.22M | -242.55%-51.61M | -24.3M | -70.7M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 83.12%-21.17M | 994.23%232.14M | -41.90%-73.24M | -70.86%-41.53M | -95.96%-138.55M | -382.22%-125.4M | -76.17%21.22M | -242.55%-51.61M | -24.3M | -70.7M |
Gross dividend payment | ||||||||||
Basic earnings per share | 83.39%-4.71 | 958.61%51.66 | -39.62%-16.28 | -68.74%-9.23 | -91.68%-30.86 | -360.09%-28.35 | -77.92%4.88 | -169.42%-11.66 | -5.47 | -16.1 |
Diluted earnings per share | 83.39%-4.71 | 989.61%51.4917 | -39.60%-16.28 | -68.26%-9.2399 | -91.68%-30.86 | -375.24%-28.35 | -76.69%4.7257 | -169.46%-11.6616 | -5.4914 | -16.1 |
Dividend per share | ||||||||||
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |